Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARSiFAL-pilot study of BAY 1067197 in chronic systolic heart failure
2013-002522-23Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing BAY 1067197 with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events. Started Oct 2013; status: completed.
02
Drugs
neladenoson bialanate
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2013-002522-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002522-23.